A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

• Status: Not yet recruiting
• Trial end date: 2024-05-18
• Target enrollment: 0
• Participant gender: All

Summary

This is a US study comparing the efficacy and safety of BDA MDI [Budesonide/Albuterol Sulfate (BDA) metered dose inhaler (MDI)] with AS [Albuterol Sulfate] MDI, both are administered as needed for up to 12 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bond Avillion 2 Development LP
• Collaborator: Parexel

Criteria

Inclusion Criteria:

1. Participant must be ≥12 years of age, at the time of signing the electronic informed consent form (eICF). For participants from 12 to <18 years of age, their parents/legal guardian must provide signed consent, as appropriate, and participants will sign an assent form.

2. Diagnosis of asthma by a prescribing healthcare professional. Documentation of asthma diagnosis should be supported by medical records or a letter from the treating physician confirming diagnosis of asthma.

3. Participants actively using SABA alone or SABA on a background of either low-dose ICS or LTRA.

4. Self-reported use of a SABA on ≥2 occasions, in response to symptoms (ie, not for exercise prophylaxis only), in the previous 2 weeks prior to enrollment.

5. An Asthma Impairment and Risk Questionnaire (AIRQ) score of ≥2 at Screening (V1) and Randomisation (V2) where applicable. Note, where screening and randomization occur on the same day, AIRQ will only be completed once.

6. Females of child-bearing potential and sexually active in heterosexual relationships must have a negative pregnancy test prior to randomization and agree to use an acceptable method of contraception throughout the study.

7. Male participants who are sexually active in heterosexual relationships must be surgically sterile or agree to use a double-barrier effective method of contraception from the date the eICF is signed until 2 weeks after their last dose.

Exclusion Criteria:

1. Any evidence of significant lung disease other than asthma, such as chronic obstructive pulmonary disease (COPD), emphysema, idiopathic pulmonary fibrosis (IPF), sarcoidosis etc.

2. Hospitalization due to asthma in the 3 months prior to enrollment or self-reported admission to the Intensive Care Unit with life-threatening asthma at any time in the past

3. Self-reported use of LABA, theophylline, anticholinergic agent, cromone or medium/high dose ICS daily, as regular maintenance asthma therapy in the 3 months prior to enrollment

4. Self-reported use of systemic corticosteroids for the treatment of asthma in the prior 6 weeks to enrollment

5. Participants with a home supply of oral corticosteroids (OCS) to be used in the case of an asthma exacerbation who are not willing to relinquish the medication to their treating physician for the duration of the study

6. Receipt of any marketed (eg, omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab) or investigational biologic for the treatment of asthma at any time in the past

7. Receipt of bronchothermoplasty

8. Use a SABA prophylactically primarily to prevent exercise induced bronchospasm (EIB) and not to treat symptoms

9. Currently receiving systemic treatment with potent cytochrome P3A4 inhibitors (eg, ketoconazole, itraconazole, and ritonavir)

10. Judgment by the Investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.

11. Previous screening, enrollment or randomization in the present study.

12. For females only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding.

13. Participants without access to a smartphone or the internet.